Heart Failure in Asia: Understanding and Managing Multimorbidity
"A closer look at a study highlighting the challenges and potential solutions for treating heart failure patients with multiple health conditions across 11 Asian regions."
Heart failure (HF) is a significant public health concern globally, and its prevalence is rising, especially in aging populations. The condition is particularly complex when it occurs alongside other chronic illnesses, a situation known as multimorbidity. This is especially challenging in diverse regions like Asia, where healthcare systems, cultural factors, and access to resources vary greatly.
A recent study published in PLOS Medicine sheds light on the issue of multimorbidity in heart failure patients across 11 Asian regions. Using data from the ASIAN-HF registry, researchers investigated the prevalence and impact of multiple co-existing health conditions on patients with heart failure. The study aimed to provide insights that could inform better management strategies and improve patient outcomes in this diverse population.
This article breaks down the key findings of this important research, making it accessible to a broader audience. We'll explore the challenges of managing multimorbidity in heart failure, discuss the implications of the study's results, and consider potential strategies for improving care for patients in Asia and beyond. Whether you're a healthcare professional, a patient living with heart failure, or simply interested in learning more about this important topic, this article provides valuable insights.
The Growing Burden of Heart Failure and Multimorbidity
Heart failure is a leading cause of morbidity and mortality worldwide, with prevalence rising as populations age across Asia and globally. When patients live with multiple chronic conditions simultaneously — a pattern known as multimorbidity — outcomes tend to worsen and management becomes substantially more complex. Accurate, region-specific data on the intersection of heart failure and multimorbidity in Asia remain limited, making it difficult to gauge the full scale of the challenge.
Treating the Whole Patient: Multimorbidity and Functional Limitation
Heart failure predominantly affects older adults, making multimorbidity and functional limitation central clinical concerns. Research shows that both multimorbidity and functional limitation are independently associated with poor outcomes in heart failure patients, and their combined effect further diminishes health-related quality of life. Current guideline-directed pharmacotherapy is often under-prescribed in multimorbid heart failure patients, partly because treatment algorithms are typically designed around single-disease models. Additionally, cluster analyses reveal that treatment response — for instance to ACE inhibitors — varies among phenotypically distinct heart failure subgroups, underscoring that one-size-fits-all approaches may be inadequate.
How Heart Failure Understanding Has Evolved
The definition and staging of heart failure have undergone significant evolution over the past century, shaped by the American College of Cardiology and American Heart Association frameworks through which most patients progress during the disease course. A pivotal shift occurred when researchers recognised that multimorbidity conditions and inflammatory modulation — alongside cardiometabolic dysregulation — could unlock new therapeutic targets, particularly for heart failure with preserved ejection fraction. Historically, multimorbidity has been recognized as common among heart failure patients, yet differences in co-occurrence patterns by heart failure type and sex have highlighted the need for a more nuanced understanding of how multiple chronic conditions interact clinically.
What is Multimorbidity and Why Does it Matter in Heart Failure?
Multimorbidity refers to the co-occurrence of two or more chronic conditions in the same individual. In the context of heart failure, this can include conditions like diabetes, hypertension, kidney disease, lung disease, and anemia. The presence of multiple chronic illnesses significantly complicates the management of heart failure, leading to poorer outcomes, increased hospitalizations, and reduced quality of life.
- Increased complexity: Managing multiple conditions simultaneously demands more from both patients and healthcare providers.
- Higher healthcare costs: More frequent hospitalizations, increased medication use, and greater need for specialized care drive up expenses.
- Reduced quality of life: The burden of managing multiple illnesses can significantly impact a patient's physical and mental well-being.
- Poorer outcomes: Multimorbidity is associated with higher mortality rates in heart failure patients.
Multimorbidity's Global Footprint in Acute Heart Failure
A large international study led by Teresa Gerhardt and colleagues found that multimorbidity is highly prevalent among patients hospitalised with acute heart failure across world regions, with the highest burden observed in high-income countries. This multimorbidity burden is associated with higher mortality, reduced prescription of guideline-directed heart failure pharmacotherapy, and increased use of potentially harmful medications. A 2026 study further investigated the prevalence and prognostic impact of multimorbidity specifically in patients hospitalised with heart failure with mildly reduced ejection fraction (HFmrEF), reflecting growing attention to this heterogeneous patient population. A systematic review of multimorbidity clusters in heart failure also highlighted that overlapping chronic conditions — including a retrospective analysis of 830 hospitalised patients in Australia — are linked to the risk of all-cause 30-day readmission.
Beyond Single-Organ Thinking: The Cardiovascular-Kidney-Metabolic Framework
A growing body of evidence argues that the traditional approach of treating heart failure and its comorbidities as separate conditions has proven insufficient. The cardiovascular-kidney-metabolic syndrome framework, described in a 2025 Circulation: Heart Failure review, emphasises the deep entanglement of cardiovascular, renal, and metabolic disorders rather than viewing them as parallel but independent problems. While interventions targeting individual components of this syndrome have shown promise, the interconnection of these systemic disorders means that addressing one axis in isolation may fail to improve — or may even worsen — overall patient outcomes. This perspective challenges researchers and clinicians to rethink how multimorbidity is conceptualised in heart failure management.
Comparing Multimorbidity Patterns Across Heart Failure Types
Multimorbidity manifests differently depending on the type of heart failure — whether with reduced, mildly reduced, or preserved ejection fraction — and these differences carry important implications for treatment selection. The absence of robust head-to-head comparative data across Asian populations makes it difficult to determine whether management strategies proven effective in Western cohorts translate directly to Asian clinical contexts. Further research that directly compares multimorbidity profiles, treatment responses, and outcomes across diverse heart failure phenotypes in Asia is needed to fill this evidence gap.
Moving Forward: Improving Care for Heart Failure Patients with Multimorbidity
The study underscores the need for tailored, integrated approaches to managing heart failure patients with multimorbidity. Strategies might include:
Cluster Analysis as a Path Toward Precision Medicine
Clustering algorithms have emerged as a promising tool for identifying distinct heart failure subgroups based on multimorbidity patterns, offering a pathway toward more personalised treatment. However, as systematic reviews have noted, the choice of clustering algorithm, modelling process, and input variables can substantially impact the subgroups identified, making standardisation and methodological rigour essential. Treatment response — for example to ACE inhibitors in HFrEF — has been found to differ across identified clusters, suggesting that tailoring pharmacotherapy to a patient's multimorbidity phenotype could improve outcomes. Continued refinement of these analytical frameworks is needed before they can be reliably translated into routine clinical practice.
What Comes Next for Heart Failure and Multimorbidity Research
Advances in data analytics and multi-omics hold potential for better characterising the biological mechanisms that link heart failure to its companion conditions. Integrating electronic health record data across Asian healthcare systems could enable large-scale studies of multimorbidity patterns that are currently lacking. Developing culturally adapted, region-specific clinical guidelines that account for the unique comorbidity burden seen in Asian heart failure patients will be a critical next step. Investments in prospective, multicentre studies across Asia are needed to move from observational associations to actionable, evidence-based management strategies.
A Worldwide Challenge With Uneven Solutions
Teresa Gerhardt and colleagues analysed data from 18,553 patients hospitalised with decompensated chronic or new-onset acute heart failure across 358 sites in 44 countries, revealing that multimorbidity patterns and their clinical consequences vary substantially by region and healthcare setting. Their findings, published in The Lancet Global Health, underscore that comorbidity-driven heterogeneity creates distinct challenges for pharmacological treatment and prognosis worldwide. The editorial commentary accompanying this research highlights that filling the gaps in our understanding of how comorbidities interact with heart failure requires addressing inequalities in data collection and clinical trial representation across low- and middle-income countries, including much of Asia.
The Patient Experience Behind the Data
Behind every statistic on heart failure and multimorbidity is a patient navigating a complex daily reality — managing multiple medications, attending numerous specialist appointments, and coping with functional limitations that reduce quality of life. The under-prescription of guideline-directed therapies in multimorbid patients reflects not only clinical uncertainty but also the practical difficulty of balancing competing treatment priorities in real-world care. Older heart failure patients with multimorbidity face particular barriers to self-management, including cognitive and physical limitations that complicate adherence to even basic regimens such as volume management. Centre-level variation in how multimorbidity is addressed suggests that systemic factors — including healthcare infrastructure, provider training, and access to multidisciplinary care — profoundly shape patient outcomes.
<ul> <li><b>Comprehensive geriatric assessment:</b> Identifying and addressing the full range of health and social needs.</li> <li><b>Individualized care plans:</b> Developing treatment plans that consider all co-existing conditions and patient preferences.</li> <li><b>Enhanced communication:</b> Improving coordination between healthcare providers and ensuring clear communication with patients.</li> <li><b>Patient education:</b> Empowering patients to actively participate in managing their health.</li> <li><b>Telehealth and remote monitoring:</b> Utilizing technology to improve access to care and monitor patients' conditions remotely.</li> </ul>
By recognizing the unique challenges and implementing targeted strategies, healthcare systems can improve the lives of heart failure patients living with multimorbidity, ensuring they receive the comprehensive and coordinated care they deserve.